English-language podcasts

Hematologic Oncology Update

Relapsed/Refractory Multiple Myeloma — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute

63 min

Listen through the publisher, then discuss the episode here or arrange an in-person Roundtable. Your city determines where to meet.

Roundtables are designed for groups of four, with a shared subject and room for everyone to speak. Come for discussion, with no dating expectation.

Featuring perspectives from Dr Sagar Lonial and Dr Paul G Richardson, including the following topics: Multiple Myeloma (0:00) Introduction: ESMO 2026; Recent FDA Approvals (1:53) Chimeric Antigen Receptor T-Cell Therapy — Dr Lonial (2:46) Bispecific Antibodies — Dr Lonial (19:16) Antibody-Drug Conjugates — Dr Richardson (37:08) Up-Front Treatment; Cereblon E3 Ligase Modulators — Dr Richardson (50:10) CME information and select publications (https://researchtopractice.com/activity/integrating-new-advances-into-community-oncology-practice-6/)

Episode information is provided by the publisher. Listening takes place on the publisher’s service.

Listen at the source ↗

Featured places to meet in Palo Alto, CA

Explore these places and arrange a conversation through ThinkMatch.

City guide for Palo Alto, CA

More from Hematologic Oncology Update

Hematologic Oncology Update

Follicular Lymphoma — Where We Are, Where We're Headed in the Use of Bispecific Antibodies

58 min

Featuring perspectives from Prof Chan Chea and Dr Matthew Matasar, including the following topics: Introduction (0:00) Prologue: Saturday Night Fever (1:35) Baby Boomers' Guide to Mechanisms of Action (3:07) Second-Line Treatment (12:36) Complications Associated with Bispecific Antibodies (23:41) Case Presentations (25:52) New Bispecific T-Cell Engagers — Surovatamig (26:24) Other Novel Agents (50:05) CME information and select publications (https://researchtopractice.com/BispecificsFL2026)

Discuss this episode

Hematologic Oncology Update

Novel Therapies for Non-Hodgkin Lymphoma — Microlearning Activity 2: An Interview with Dr Matthew Lunning on Novel Combination Regimens

18 min

Featuring an interview with Dr Matthew Lunning, including the following topics: Bispecific antibody/antibody-drug conjugate combinations (0:00) A man in his late 90s with mantle cell lymphoma — Ann LaCasce, MD, MMSc (8:07) CME information and select publications (https://researchtopractice.com/ASCO2026/NHL/Micro/2)

Discuss this episode

Hematologic Oncology Update

Diffuse Large B-Cell Lymphoma — A Grand Rounds Program

62 min

Featuring a presentation by Dr Matthew Matasar, including the following topics: Selection of First-Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) (0:00) Clinician Survey Results Regarding First-Line Treatment of DLBCL (11:41) Current and Future Roles of Monoclonal and Bispecific Antibodies in Therapy for Relapsed/Refractory (R/R) DLBCL (16:01) Clinician Survey Results Regarding the Use of Monoclonal and Bispecific Antibodies for R/R DLBCL (28:47) Evidence-Based Incorporation of Antibody-Drug Conjugates (ADCs) into the Management of R/R DLBCL (34:34) Clinician Survey Results Regarding the Use of ADCs for R/R DLBCL (46:31) Discussion of Questions from the Community (50:20) CME information and select publications (https://researchtopractice.com/GR2026/DLBCL)

Discuss this episode

Community Poll

Colleges should publish clear information about costs and likely graduate outcomes.

Share your view, then see how readers voted. No sign-in required. This poll is shared across stories.

Do you agree or disagree?

Choose one answer

Common Quandary

A Common Quandary to discuss

Another conversation to explore, separate from this news story.

A donor's family wants to hear their loved one's heart beating in you. Do you meet them?

A transplant recipient receives a letter from the donor's family asking to meet. The recipient feels profound gratitude but also discomfort and wants their recovery to remain private and separate from another family's grief.

Can receiving an extraordinary gift create a personal obligation to strangers?

Explore this quandary